Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the ...
Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and paediatric patients. The drug has been specifically authorised for the ...
Zacks.com on MSN5d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EUPfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
GlobalData on MSN5d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophiliaThe European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI ...
In his new role, Dr. Boshoff wi NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI ...
HYMPAVZI is a once-weekly subcutaneous treatment option for individuals with severe haemophilia A or B. Credit: Andrey_Popov/Shutterstock. The European Commission (EC ...
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of bleeding episodes in patients 12 years of age and older ...
(RTTNews) - Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI (marstacimab) to treat adults and adolescents with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback